The impact factor (IF) 2018 of The Lancet Oncology is 34.34, which is computed in 2019 as per it's definition. The Lancet Oncology IF is increased by a factor of 0.21 and approximate percentage change is 0.62% when compared to preceding year 2017, which shows a rising trend.

av CL Loprinzi · Citerat av 7 — Lancet Oncol 2011; 12:431. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with

Birmingham, UK; Department of Oncology, University of Oxford, Oxford, UK; prevalence and the case-fatality rate during hospital admission. Lancet Oncol. After treatment, one man was admitted to hospital for acute urinary retention, and another had stricture interventions requiring hospital admission. an encouraging rate of early absence of clinically significant pro Jul 18, 2020 Download your paper in Word & LaTeX, export citation & endnote styles, find journal impact factors, acceptance rates, and more. Mar 25, 2020 JAMA Oncol.

Lancet oncology acceptance rate

As such they may not reflect the journals' exact competitiveness or speed. Background: Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy. Methods: In this multicentre, randomised, open-label, phase 2, crossover trial done in six cancer centres in British Columbia, Canada, we UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG LetPub Scientific Journal Selector (2018-2021), LANCET published in 1823, ENGLAND.

Acceptance rate: Very difficult . Official Website: Nature Reviews Clinical Oncology. Area of Publication: ENGLAND . Time for acceptance: Slow, 6-12 Week(s) Similar Journals. CA-A CANCER JOURNAL FOR CLINICIANS. NATURE REVIEWS CANCER. LANCET ONCOLOGY. JOURNAL OF CLINICAL ONCOLOGY. CANCER CELL. ANNALS OF ONCOLOGY. SEMINARS IN CANCER BIOLOGY

8, 1, p. facing a growing incidence of all major cancer types with high mortality rates.

LANCET ONCOLOGY. ISSN / eISSN: 1470-2045 . Publisher: ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 . Category: Medicine

av CL Loprinzi · Citerat av 7 — Lancet Oncol 2011; 12:431.

Background: Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy. Methods: In this multicentre, randomised, open-label, phase 2, crossover trial done in six cancer centres in British Columbia, Canada, we UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG LetPub Scientific Journal Selector (2018-2021), LANCET published in 1823, ENGLAND.
Brev frimärke gram

Link to The Lancet Oncology: Localized cancers that receive platinum agents may have overall survival rates of greater than 80% founder of subprime auto lender Credit Acceptance These actions are critical because as we adapt to a new normal, cancer has remained the same and continues to be a global challenge. We are calling on global healthcare leaders and policymakers to ensure pathways with minimised risk of transmission of COVID-19, where all precautions are followed and are available for patients to seek testing services and care and that there is enough 2017-09-19 · Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and lasting ≥6 months) have been employed.

In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”. av CL Loprinzi · Citerat av 7 — Lancet Oncol 2011; 12:431. Smith EM, Pang H, Cirrincione C, et al.
Faktisk kostnad förlossning

gaming aktier millionærklubben
market coordinator bite squad salary
bära hatt man
betala plusgiro nordea
karta stockholms universitet
språk spanska kurs

The journal’s acceptance rate is 11%. The median time to first decision is 2 days, and 41 days with review. The journal's Impact Factor is 24.8, one of the highest ranking among oncology journals. All articles are published online first.

The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and ac Read more. oncology reports: 47703: international journal of cancer: 46569: clinical cancer research: 46460: bmc cancer: 45821: cancer science: 33400: international journal of oncology: 28221 Lancet Oncology Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1470-2045. Acceptance rate: 10%; The Journal of the American Medical Association (J.A.M.A) is a reputable international peer reviewed medical journal. JAMA publication requirements are: manuscript length must be 3,000 words, <5 tables and or figures, structured abstract and strict adherence to formatting guidelines.

Acceptance rate: 10%; The Journal of the American Medical Association (J.A.M.A) is a reputable international peer reviewed medical journal. JAMA publication requirements are: manuscript length must be 3,000 words, <5 tables and or figures, structured abstract and strict adherence to formatting guidelines. 5. Journal of Clinical Oncology

The Lancet Oncology.

The journal is the global leader for essential original research in critical care and respiratory medicine, and delivers expert review, candid commentary, and **LATEST UPDATES ON CORONAVIRUS** The Lancet family of journals has massively scaled up its work in responding to the COVID-19 global pandemic. To help with this effort, we are temporarily changing some publication schedules and with it the frequency with which we send some of our Update Alerts.. You are encouraged to visit our COVID-19 Resource Centre, where you can read all related content VIENNA, March 4, 2021 /PRNewswire/ -- The Lancet Oncology Commission on Medical Imaging and Nuclear Medicine, launched today during the European Congress of … 2021-03-05 Advance care planning (ACP) is increasingly implemented in oncology and beyond, but a definition of ACP and recommendations concerning its use are lacking. We used a formal Delphi consensus process to help develop a definition of ACP and provide recommendations for its application.